Regencell Bioscience Holdings Limited (RGC)
NASDAQ: RGC · Real-Time Price · USD
25.67
-9.20 (-26.38%)
At close: Mar 28, 2025, 4:00 PM
25.51
-0.16 (-0.62%)
After-hours: Mar 28, 2025, 7:55 PM EDT
RGC Employees
Regencell Bioscience Holdings had 12 employees as of June 30, 2024. The number of employees did not change compared to the previous year.
Employees
12
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$358,486
Market Cap
334.04M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 12 | 0 | - |
| Jun 30, 2023 | 12 | -1 | -7.69% |
| Jun 30, 2022 | 13 | -1 | -7.14% |
| Jun 30, 2021 | 14 | - | - |
RGC News
- 2 years ago - Regencell Bioscience's Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial - Business Wire
- 2 years ago - Slow And Steady Wins The Race With Regencell Bioscience - Seeking Alpha
- 3 years ago - Sector Rotation And 9 Stocks To Watch During A Recession - Benzinga
- 3 years ago - Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period - Business Wire
- 3 years ago - Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO - Business Wire
- 3 years ago - Regencell Describes Their Traditional Chinese Medicine ("TCM") Treatments and Recent Efficacy Trial Results in New Video Interview on SNN Network - Accesswire
- 3 years ago - Regencell Bioscience's COVID-19 Candidate Shows Encouraging Action On Mild To Moderate Symptoms - Benzinga
- 3 years ago - Regencell Bioscience's Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial - Business Wire